Sanofi (NASDAQ:SNY) Cut to Hold at StockNews.com

StockNews.com lowered shares of Sanofi (NASDAQ:SNY) from a buy rating to a hold rating in a report issued on Thursday.

Separately, Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Performance

Shares of NASDAQ:SNY opened at $46.80 on Thursday. The stock has a market capitalization of $118.77 billion, a P/E ratio of 23.88, a P/E/G ratio of 1.24 and a beta of 0.58. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97. The business has a 50-day moving average price of $51.02 and a two-hundred day moving average price of $52.07.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. During the same period in the previous year, the firm posted $2.55 earnings per share. Sanofi’s revenue for the quarter was up 12.3% compared to the same quarter last year. Equities analysts predict that Sanofi will post 4.27 earnings per share for the current year.

Hedge Funds Weigh In On Sanofi

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. POM Investment Strategies LLC bought a new position in shares of Sanofi in the 2nd quarter valued at about $25,000. Northwest Investment Counselors LLC bought a new position in Sanofi in the third quarter valued at approximately $29,000. Concord Wealth Partners increased its position in shares of Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after purchasing an additional 363 shares during the last quarter. Arrow Financial Corp bought a new stake in shares of Sanofi during the 2nd quarter worth approximately $35,000. Finally, Fortitude Family Office LLC boosted its holdings in shares of Sanofi by 708.6% in the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after buying an additional 659 shares during the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.